dc.contributor.author | Tüzün, Erdem | |
dc.contributor.author | Ulusoy, Canan Aysel | |
dc.contributor.author | Eraksoy, Mefküre | |
dc.contributor.author | Yılmaz, Vuslat | |
dc.contributor.author | Gündüz, Tuncay | |
dc.contributor.author | Karaaslan, Zerrin | |
dc.contributor.author | Kürtüncü, Murat | |
dc.contributor.author | Akçay, Halil İbrahim | |
dc.contributor.author | Altunrende, Burcu | |
dc.contributor.author | Türkoğlu, Recai | |
dc.date.accessioned | 2021-12-10T09:57:37Z | |
dc.date.available | 2021-12-10T09:57:37Z | |
dc.identifier.citation | Karaaslan Z., Kürtüncü M., Akçay H. İ. , Gündüz T., Altunrende B., Türkoğlu R., Eraksoy M., Ulusoy C. A. , Yılmaz V., Tüzün E., "CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients", European Neurology, cilt.2, ss.1-3, 2021 | |
dc.identifier.issn | 0014-3022 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_1f31487f-93f3-4db3-af71-7cddcc63dc73 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/168881 | |
dc.identifier.uri | https://www.karger.com/Article/FullText/517770 | |
dc.identifier.uri | https://doi.org/10.1159/000517770 | |
dc.language.iso | eng | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Sağlık Bilimleri | |
dc.title | CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients | |
dc.type | Makale | |
dc.relation.journal | European Neurology | |
dc.contributor.department | İstanbul Üniversitesi , Aziz Sancar Deneysel Tıp Araştırma Enstitüsü , Sinir Bilimi Ana Bilim Dalı | |
dc.identifier.volume | 2 | |
dc.identifier.startpage | 1 | |
dc.identifier.endpage | 3 | |
dc.contributor.firstauthorID | 2696902 | |